206 related articles for article (PubMed ID: 33643691)
1. Inflammatory B cells correlate with failure to checkpoint blockade in melanoma patients.
de Jonge K; Tillé L; Lourenco J; Maby-El Hajjami H; Nassiri S; Racle J; Gfeller D; Delorenzi M; Verdeil G; Baumgaertner P; Speiser DE
Oncoimmunology; 2021 Feb; 10(1):1873585. PubMed ID: 33643691
[TBL] [Abstract][Full Text] [Related]
2. B cells and tertiary lymphoid structures promote immunotherapy response.
Helmink BA; Reddy SM; Gao J; Zhang S; Basar R; Thakur R; Yizhak K; Sade-Feldman M; Blando J; Han G; Gopalakrishnan V; Xi Y; Zhao H; Amaria RN; Tawbi HA; Cogdill AP; Liu W; LeBleu VS; Kugeratski FG; Patel S; Davies MA; Hwu P; Lee JE; Gershenwald JE; Lucci A; Arora R; Woodman S; Keung EZ; Gaudreau PO; Reuben A; Spencer CN; Burton EM; Haydu LE; Lazar AJ; Zapassodi R; Hudgens CW; Ledesma DA; Ong S; Bailey M; Warren S; Rao D; Krijgsman O; Rozeman EA; Peeper D; Blank CU; Schumacher TN; Butterfield LH; Zelazowska MA; McBride KM; Kalluri R; Allison J; Petitprez F; Fridman WH; Sautès-Fridman C; Hacohen N; Rezvani K; Sharma P; Tetzlaff MT; Wang L; Wargo JA
Nature; 2020 Jan; 577(7791):549-555. PubMed ID: 31942075
[TBL] [Abstract][Full Text] [Related]
3. Tertiary lymphoid structures improve immunotherapy and survival in melanoma.
Cabrita R; Lauss M; Sanna A; Donia M; Skaarup Larsen M; Mitra S; Johansson I; Phung B; Harbst K; Vallon-Christersson J; van Schoiack A; Lövgren K; Warren S; Jirström K; Olsson H; Pietras K; Ingvar C; Isaksson K; Schadendorf D; Schmidt H; Bastholt L; Carneiro A; Wargo JA; Svane IM; Jönsson G
Nature; 2020 Jan; 577(7791):561-565. PubMed ID: 31942071
[TBL] [Abstract][Full Text] [Related]
4. Association of IL-36γ with tertiary lymphoid structures and inflammatory immune infiltrates in human colorectal cancer.
Weinstein AM; Giraldo NA; Petitprez F; Julie C; Lacroix L; Peschaud F; Emile JF; Marisa L; Fridman WH; Storkus WJ; Sautès-Fridman C
Cancer Immunol Immunother; 2019 Jan; 68(1):109-120. PubMed ID: 30315348
[TBL] [Abstract][Full Text] [Related]
5. The 12-CK Score: Global Measurement of Tertiary Lymphoid Structures.
Li R; Berglund A; Zemp L; Dhillon J; Putney R; Kim Y; Jain RK; Grass GD; Conejo-Garcia J; Mulé JJ
Front Immunol; 2021; 12():694079. PubMed ID: 34267760
[TBL] [Abstract][Full Text] [Related]
6. A B-cell or a key player? The different roles of B-cells and antibodies in melanoma.
Rodgers CB; Mustard CJ; McLean RT; Hutchison S; Pritchard AL
Pigment Cell Melanoma Res; 2022 May; 35(3):303-319. PubMed ID: 35218154
[TBL] [Abstract][Full Text] [Related]
7. Pan-cancer analysis of genomic properties and clinical outcome associated with tumor tertiary lymphoid structure.
Lin Z; Huang L; Li S; Gu J; Cui X; Zhou Y
Sci Rep; 2020 Dec; 10(1):21530. PubMed ID: 33299035
[TBL] [Abstract][Full Text] [Related]
8. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.
Chen PL; Roh W; Reuben A; Cooper ZA; Spencer CN; Prieto PA; Miller JP; Bassett RL; Gopalakrishnan V; Wani K; De Macedo MP; Austin-Breneman JL; Jiang H; Chang Q; Reddy SM; Chen WS; Tetzlaff MT; Broaddus RJ; Davies MA; Gershenwald JE; Haydu L; Lazar AJ; Patel SP; Hwu P; Hwu WJ; Diab A; Glitza IC; Woodman SE; Vence LM; Wistuba II; Amaria RN; Kwong LN; Prieto V; Davis RE; Ma W; Overwijk WW; Sharpe AH; Hu J; Futreal PA; Blando J; Sharma P; Allison JP; Chin L; Wargo JA
Cancer Discov; 2016 Aug; 6(8):827-37. PubMed ID: 27301722
[TBL] [Abstract][Full Text] [Related]
9. B Cells in Patients With Melanoma: Implications for Treatment With Checkpoint Inhibitor Antibodies.
Willsmore ZN; Harris RJ; Crescioli S; Hussein K; Kakkassery H; Thapa D; Cheung A; Chauhan J; Bax HJ; Chenoweth A; Laddach R; Osborn G; McCraw A; Hoffmann RM; Nakamura M; Geh JL; MacKenzie-Ross A; Healy C; Tsoka S; Spicer JF; Papa S; Barber L; Lacy KE; Karagiannis SN
Front Immunol; 2020; 11():622442. PubMed ID: 33569063
[TBL] [Abstract][Full Text] [Related]
10. B cells and the coordination of immune checkpoint inhibitor response in patients with solid tumors.
Flippot R; Teixeira M; Rey-Cardenas M; Carril-Ajuria L; Rainho L; Naoun N; Jouniaux JM; Boselli L; Naigeon M; Danlos FX; Escudier B; Scoazec JY; Cassard L; Albiges L; Chaput N
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38631710
[TBL] [Abstract][Full Text] [Related]
11. VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma.
Wu X; Giobbie-Hurder A; Liao X; Lawrence D; McDermott D; Zhou J; Rodig S; Hodi FS
Cancer Immunol Res; 2016 Oct; 4(10):858-868. PubMed ID: 27549123
[TBL] [Abstract][Full Text] [Related]
12. Identification and Characterization of Tertiary Lymphoid Structures in Murine Melanoma.
Rodriguez AB; Peske JD; Engelhard VH
Methods Mol Biol; 2018; 1845():241-257. PubMed ID: 30141017
[TBL] [Abstract][Full Text] [Related]
13. B cells in tertiary lymphoid structures are associated with favorable prognosis in gastric cancer.
Sakimura C; Tanaka H; Okuno T; Hiramatsu S; Muguruma K; Hirakawa K; Wanibuchi H; Ohira M
J Surg Res; 2017 Jul; 215():74-82. PubMed ID: 28688665
[TBL] [Abstract][Full Text] [Related]
14. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
15. High infiltration of B cells in tertiary lymphoid structures, TCR oligoclonality, and neoantigens are part of esophageal squamous cell carcinoma microenvironment.
Barros LRC; Souza-Santos PT; Pretti MAM; Vieira GF; Bragatte MAS; Mendes MFA; De Freitas MV; Scherer NM; De Oliveira IM; Rapozo DCM; Fernandes PV; Simão TA; Soares-Lima SC; Boroni M; Ribeiro Pinto LF; Bonamino MH
J Leukoc Biol; 2020 Oct; 108(4):1307-1318. PubMed ID: 32827331
[TBL] [Abstract][Full Text] [Related]
16. Designed Methods for the Sorting of Tertiary Lymphoid Structure-Immune Cell Populations.
Devi-Marulkar P; Kaplon H; Dieu-Nosjean MC; Lawand M
Methods Mol Biol; 2018; 1845():189-204. PubMed ID: 30141014
[TBL] [Abstract][Full Text] [Related]
17. Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma.
van Hooren L; Vaccaro A; Ramachandran M; Vazaios K; Libard S; van de Walle T; Georganaki M; Huang H; Pietilä I; Lau J; Ulvmar MH; Karlsson MCI; Zetterling M; Mangsbo SM; Jakola AS; Olsson Bontell T; Smits A; Essand M; Dimberg A
Nat Commun; 2021 Jul; 12(1):4127. PubMed ID: 34226552
[TBL] [Abstract][Full Text] [Related]
18. IL-32γ potentiates tumor immunity in melanoma.
Gruber T; Kremenovic M; Sadozai H; Rombini N; Baeriswyl L; Maibach F; Modlin RL; Gilliet M; von Werdt D; Hunger RE; Seyed Jafari SM; Parisi G; Abril-Rodriguez G; Ribas A; Schenk M
JCI Insight; 2020 Sep; 5(18):. PubMed ID: 32841222
[TBL] [Abstract][Full Text] [Related]
19. Clonality of CD4
Arakawa A; Vollmer S; Tietze J; Galinski A; Heppt MV; Bürdek M; Berking C; Prinz JC
Front Immunol; 2019; 10():1336. PubMed ID: 31275310
[TBL] [Abstract][Full Text] [Related]
20. TERT mutations correlate with higher TMB value and unique tumor microenvironment and may be a potential biomarker for anti-CTLA4 treatment.
Li H; Li J; Zhang C; Zhang C; Wang H
Cancer Med; 2020 Oct; 9(19):7151-7160. PubMed ID: 32810393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
